GlassScriptPhysician profile
Mohsen Soofian
NPI 1265880520
$447.23
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $142 · 2021: $123 · 2022: $153 · 2024: $29.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $142.28 | 2020 | |
| Viiv Healthcare Company | $125.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.84 | 2021-2022 | |
| Becton, Dickinson and Company | $29.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $23.61 | 2021 | |
| Pfizer INC. | $15.72 | 2021 | |
| Lilly USA, LLC | $15.22 | 2021 | |
| Baudax Bio INC. | $13.56 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Soofian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.